Objective: Renal allograft function monitoring has traditionally relied on functional markers such as creatinine level. Such markers are insensitive, and invasive ultrasound-guided protocol biopsies are used for allograft evaluation. This pilot study evaluates the association between renal perfusion measured noninvasively with contrast-enhanced MRI and the histologic severity of chronic allograft nephropathy.
Subjects And Methods: Chronic allograft nephropathy severity was estimated from protocol biopsy specimens using the chronic allograft damage index. We prospectively selected four patients considered to have severe chronic allograft nephropathy (chronic allograft damage index score > 4) and six patients considered to have stable allograft function (chronic allograft damage index score
Results: We observed a statistically significant association between chronic allograft damage index score and MRI perfusion. MRI perfusion was significantly lower in the four patients with a chronic allograft damage index score of > 4 than in the other patients (1.94 vs 2.43 mL/min/g, respectively; p = 0.03). The effect size for this difference was large (d = 1.7). The R(2) for the linear regression model was 0.53.
Conclusion: We observed an association between contrast-enhanced MRI renal perfusion and chronic allograft nephropathy severity. Further studies are needed to confirm this preliminary finding and to evaluate the role of contrast-enhanced MRI renal perfusion as a screening test for allograft dysfunction and potential utility in patient management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2214/AJR.09.2912 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation.
Cell Transplant
January 2025
Department of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, China.
Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. Effective interventions to reduce DSAs are still needed, and the cost of the current therapies is relatively high.
View Article and Find Full Text PDFFollow-up biopsies with microvascular inflammation and persistent donor specific antibodies identify ongoing rejection in pediatric kidney transplant recipients.
Pediatr Nephrol
January 2025
Department of Pediatrics, University of California San Diego, 3020 Children's Way MC 5137, San Diego, CA, 92123, USA.
Background: Inadequate treatment of acute rejection (AR) in pediatric kidney transplant recipients (KTR) can contribute to early allograft failure. Serum creatinine is an insensitive marker of allograft function, especially in the pediatric population, and may not detect ongoing rejection after treatment. We evaluated the utility of follow-up biopsies to detect persistent inflammation and future episodes of rejection.
View Article and Find Full Text PDFMETTL3 Potentiates M2 Macrophage-Driven MMT to Aggravate Renal Allograft Fibrosis via the TGF-β1/Smad3 Pathway.
Adv Sci (Weinh)
January 2025
Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
METTL3, a key enzyme in N6-methyladenosine (m6A) modification, plays a crucial role in the progression of renal fibrosis, particularly in chronic active renal allograft rejection (CAR). This study explored the mechanisms by which METTL3 promotes renal allograft fibrosis, focusing on its role in the macrophage-to-myofibroblast transition (MMT). Using a comprehensive experimental approach, including TGF-β1-induced MMT cell models, METTL3 conditional knockout (METTL3 KO) mice, and renal biopsy samples from patients with CAR, the study investigates the involvement of METTL3/Smad3 axis in driving MMT and renal fibrosis during the episodes of CAR.
View Article and Find Full Text PDFTissue Selective Ultrasonic Debridement with Cryopreserved Human Skin Allograft to Heal a Chronic Wound: A Case Report.
J Am Podiatr Med Assoc
January 2025
†Jesse Brown VA Medical Center, Chicago, IL.
Tissue selective ultrasonic debridement is a new method of debriding chronic wounds that prepares the wound for advanced tissue application. This article presents the case of an 89-year-old woman with a chronic nonhealing wound to her lateral distal leg. The wound had a significant amount of biofilm and fibrous slough.
View Article and Find Full Text PDFRationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study).
BMC Cancer
January 2025
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: Even though major improvements have been made in the treatment of myeloma, the majority of patients eventually relapse or progress. Patients with multiple myeloma who relapse after initial high-dose chemotherapy with autologous stem cells have a median progression free survival up to 2-3 years, depending on risk factors such as previous remission duration. In recent years, growing evidence has suggested that allogeneic stem cell transplantation could be a promising treatment option for patients with relapsed or progressed multiple myeloma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!